Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Author:

Zhao Juanjuan1,Yuan Quan23,Wang Haiyan1,Liu Wei23,Liao Xuejiao1,Su Yingying23,Wang Xin1,Yuan Jing4,Li Tingdong23,Li Jinxiu5,Qian Shen1,Hong Congming23,Wang Fuxiang4,Liu Yingxia46,Wang Zhaoqin6,He Qing6,Li Zhiyong3,He Bin23,Zhang Tianying23,Fu Yang7,Ge Shengxiang23,Liu Lei16,Zhang Jun23,Xia Ningshao23,Zhang Zheng16ORCID

Affiliation:

1. Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen, China

2. The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health and School of Life Science, Xiamen University, Xiamen, China

3. School of Public Health, Xiamen University, Xiamen, China

4. Department for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, China

5. Department of Critical Care Medicine, Shenzhen Third People’s Hospital, Shenzhen, China

6. The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China

7. School of Medicine, Southern University of Science and Technology, Shenzhen, China

Abstract

Abstract Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated. Methods 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during hospitalization were tested for total antibodies (Ab), IgM, and IgG against SARS-CoV-2. The dynamics of antibodies with disease progress were analyzed. Results Among 173 patients, the seroconversion rates for Ab, IgM, and IgG were 93.1%, 82.7%, and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might be due to the lack of blood samples at the later stage of illness. The median seroconversion times for Ab, IgM, and then IgG were days 11, 12, and 4, respectively. The presence of antibodies was <40% among patients within 1 week of onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM), and 79.8% (IgG) by day 15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15–39. Combining RNA and antibody detection significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (P < .001), even in the early phase of 1 week from onset (P = .007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (P = .006). Conclusions Antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.

Funder

Bill and Melinda Gates Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference12 articles.

1. Cli;Guan;N Engl J Med

2. Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan;Wang

3. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study;Chen;Lancet,2020

4. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3